Shots:
- AbbVie selects two DUB targets to advance it to the next stage of drug discovery based on the results from in vitro & in vivo studies for which Mission will receive a $20M as milestones
- As per 2018 agreement, the companies collaborated to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases. AbbVie had the option to obtain exclusive rights to develop & commercialize inhibitors of selected DUB targets for which Mission will receive milestones along with royalties for each commercialized product
- DUBs help to maintain cell health & regulates the degradation of proteins including the amyloid-beta and alpha-synuclein molecules
Click here to read full press release/ article | Ref: Mission Therapeutics | Image: Wall Street Journal
The post AbbVie Receives $20M Milestone in its DUB Targets Collaboration with Mission to Treat Alzheimer and Parkinson Diseases first appeared on PharmaShots.
